Get the Stockscreener App
28.76
8.94%
2.36
After Hours:
28.76
Odyssey Therapeutics Inc stock is traded at $28.76, with a volume of 268.97K.
It is up +8.94% in the last 24 hours and up +44.09% over the past month.
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.
See More
Previous Close:
$26.40
Open:
$26.24
24h Volume:
268.97K
Relative Volume:
0.95
Market Cap:
$1.38B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-9.2927
EPS:
-3.0949
Net Cash Flow:
-
1W Performance:
+18.06%
1M Performance:
+44.09%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$25.71
$29.05
1-Week Range:
$22.89
$29.05
52-Week Range:
$15.10
$29.05
Odyssey Therapeutics Inc Stock (ODTX) Company Profile
Name
Odyssey Therapeutics Inc
Sector
Industry
Phone
(212) 841-1000
Address
51 SLEEPER STREET, BOSTON
Compare ODTX vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ODTX
Odyssey Therapeutics Inc
|
28.76 | 1.19B | 0 | 0 | 0 | -3.0949 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Odyssey Therapeutics Inc Stock (ODTX) Latest News
Top Odyssey Therapeutics (ODTX) Competitors 2026 - MarketBeat
Odyssey Therapeutics Hits $900M Valuation In Nasdaq Debut, Stock Climbs 13% Before Diving Lower - Stocktwits
Odyssey Therapeutics (ODTX) Stock Trends and Sentiment 2026 - marketbeat.com
J.P. Morgan Maintains Odyssey Therapeutics(ODTX.US) With Buy Rating, Raises Target Price to $29 - Moomoo
Odyssey Therapeutics (ODTX) Looks Fully Valued As Earnings And Evotec Deal Refocus Attention - Yahoo Finance
Odyssey Therapeutics (ODTX) Stock Looks Reasonable As AI Research News Lands - Sahm
Odyssey Therapeutics Ord Shs (Proposed) (ODTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Evotec and Odyssey Forge AI-Powered Drug Discovery Pact Targeting Autoimmune Diseases - finance.biggo.com
Odyssey Therapeutics (NASDAQ:ODTX) Given New $29.00 Price Target at JPMorgan Chase & Co. - MarketBeat
ODTX Price Today: Odyssey Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - mexc.co
EQS-News: Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases - sharewise.com
Odyssey Therapeutics: Q2 Earnings Snapshot - marketscreener.com
Odyssey Therapeutics, Inc. Q2 2026: Revenue $0 EPS $(1.74) — 10-Q Summary - TradingView
Biotech Stocks At 52-Week HighsBVS, TVTX, ODTX, CRL Climb With Q2 Results, ACRS - RTTNews
Evotec and Odyssey Pair AI With Lab Tests for Immune Diseases - Stock Titan
Evotec Se and Odyssey Therapeutics, Inc. Enter Ai-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases - marketscreener.com
Evotec : and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases - marketscreener.com
Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases - Yahoo Finance
Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Odyssey Therapeutics reports Q2 2026 net loss $52.8M; cash $433.1M to fund into 2H 2028 - TradingView
Odyssey Therapeutics, Inc. Revenue Breakdown – NASDAQ:ODTX - TradingView
ODTX|Odyssey Therapeutics Ord Shs (Proposed)|Price:18.660|Chg%:+0.990 - TradingKey
Odyssey Therapeutics (ODTX) Earnings Date and Reports 2026 - MarketBeat
Enterprise value to EBITDA forward of Odyssey Therapeutics, Inc. – NASDAQ:ODTX - TradingView
Enterprise value to revenue forward of Odyssey Therapeutics, Inc. – NASDAQ:ODTX - TradingView
Price to book forward of Odyssey Therapeutics, Inc. – NASDAQ:ODTX - TradingView
Price to earnings forward of Odyssey Therapeutics, Inc. – NASDAQ:ODTX - TradingView
Price to sales forward of Odyssey Therapeutics, Inc. – NASDAQ:ODTX - TradingView
Odyssey Therapeutics prices upsized IPO at $18 per share - Investing.com
Odyssey Therapeutics Inc (ODTX) Dividend News Alerts - DividendInvestor.com
Enterprise value to EBIT forward of Odyssey Therapeutics, Inc. – NASDAQ:ODTX - TradingView
Form 8K ODYSSEY THERAPEUTICS For: 23 June By Investing.com - Investing.com Nigeria
Odyssey posts June 2026 corporate presentation highlighting OD-001 Phase 2a results and $464M pro forma cash - TradingView
Odyssey Therapeutics (NASDAQ: ODTX) details I&I pipeline, OD-001 data and cash - Stock Titan
ODTX Stock Price and Chart — NASDAQ:ODTX - TradingView
Odyssey Therapeutics, Inc.(NasdaqCM: ODTX) added to S&P TMI Index - marketscreener.com
Odyssey Therapeutics, Inc. (ODTX) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Analysts Offer Insights on Healthcare Companies: Odyssey Therapeutics, Inc. (ODTX), Capricor Therapeutics (CAPR) and Medtronic (MDT) - The Globe and Mail
Odyssey Therapeutics Inc Stock (ODTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Odyssey Therapeutics Inc Stock (ODTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Dimension Capital II, L.P. | Director |
May 08 '26 |
Buy |
18.00 |
1,111,111 |
19,999,998 |
3,333,516 |
| SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner |
May 11 '26 |
Buy |
18.00 |
555,555 |
9,999,990 |
1,831,383 |
| SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner |
May 11 '26 |
Sale |
18.00 |
1,780 |
32,040 |
440,981 |
| LEIDEN JEFFREY M | Director |
May 08 '26 |
Buy |
20.00 |
5,000 |
100,000 |
270,198 |
| Haas Jason | Chief Financial Officer |
May 08 '26 |
Buy |
20.00 |
1,000 |
20,000 |
62,908 |
| Li Nan (LN) | Director |
May 11 '26 |
Buy |
18.00 |
1,111,111 |
19,999,998 |
3,333,516 |
| Chu Shelley | Director |
May 11 '26 |
Buy |
18.00 |
11,111 |
199,998 |
11,111 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):